ccfdc2a2-bb01-41c2-9ef1-98bbd1cfae22
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.400
- MYC_TARGETS_V2+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- ADIPOGENESIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- HEME_METABOLISM+0.200
- HYPOXIA+0.200
- MTORC1_SIGNALING+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- COAGULATION-0.300
- COMPLEMENT-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- KRAS_SIGNALING_UP-0.300
- ANDROGEN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613749 | — | C | 0.889 |
| 2 | TCGA-CV-7253-01A-11R-2016-07 | — | — | 0.856 |
| 3 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.855 |
| 4 | s0112311 | — | — | 0.828 |
| 5 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.823 |
| 6 | MDT-AP-0580 | Med | Medulloblastoma | 0.820 |
| 7 | TCGA-77-6843-01A-11R-1949-07 | — | cohortSQ2 | 0.818 |
| 8 | TCGA-UF-A71E-01A-31R-A34R-07 | — | — | 0.817 |
| 9 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.815 |
| 10 | MDT-AP-0439 | Med | Medulloblastoma | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |